Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia
New England Journal of Medicine · 20.02.2025 · 392 (8) · 737-747
DOI: 10.1056/nejmoa2409501 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift New England Journal of Medicine, erschienen am 20.02.2025. Verfasst von John L Sapp und 26 weiteren Autor:innen. Beteiligte Einrichtung: QEII Health Sciences Centre, Dalhousie University, Halifax, NS, Canada. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Catheter Ablation, Myocardial Infarction, Tachycardia, Ventricular. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Johnson and Johnson, CIHR, Heart and Stroke Foundation of Canada.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- QEII Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
- Western University, London, ON, Canada.
- Vanderbilt University Medical Center, Nashville.
- Population Health Research Institute, Hamilton, ON, Canada.
- University of Ottawa Heart Institute, Ottawa.
- McGill University Health Centre, Montreal.
ORCID-Profile: John L Sapp, Jeff S Healey
Förderung
- Johnson and Johnson
- CIHR
- Heart and Stroke Foundation of Canada
- Dalhousie University Faculty of Medicine
- Dalhousie University Department of Medicine
- Nova Scotia Health Authority
- Canadian Institutes of Health Research
- Cardiac Arrhythmia Network of Canada
Zitieren
APA
Sapp, J. L., Tang, A. S. L., Parkash, R., Stevenson, W. G., Healey, J. S., Gula, L. J., Nair, G. M., Essebag, V., Rivard, L., Roux, J. F., Nery, P. B., Sarrazin, J. F., Amit, G., Raymond, J. M., Deyell, M., Lane, C., Sacher, F., de Chillou, C., Kuriachan, V., …, & VANISH2 Study Team (2025). Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. New England Journal of Medicine, 392(8), 737-747. https://doi.org/10.1056/nejmoa2409501
Vancouver
Sapp JL, Tang ASL, Parkash R, Stevenson WG, Healey JS, Gula LJ, et al. Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. New England Journal of Medicine. 2025;392(8):737-747. doi:10.1056/nejmoa2409501
BibTeX
@article{Sapp2025,
author = {Sapp, John L and Tang, Anthony S L and Parkash, Ratika and Stevenson, William G and Healey, Jeff S and Gula, Lorne J and Nair, Girish M and Essebag, Vidal and Rivard, Lena and Roux, Jean-Francois and Nery, Pablo B and Sarrazin, Jean-Francois and Amit, Guy and Raymond, Jean-Marc and Deyell, Marc and Lane, Chris and Sacher, Frederic and de Chillou, Christian and Kuriachan, Vikas and AbdelWahab, Amir and Nault, Isabelle and Dyrda, Katia and Wilton, Stephen and Jolly, Umjeet and Kanagasundram, Arvindh and Wells, George A and VANISH2 Study Team, VANISH2 Study Team},
title = {Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {8},
pages = {737--747},
doi = {10.1056/nejmoa2409501}
}
EUVIMED